Zymeworks’ Zanidatamab Receives the NMPA’s Conditional Approval for the Treatment of Biliary Tract Cancer

Shots:The NMPA has granted conditional approval to zanidatamab for the treatment of pts with previously treated, inoperable or metastatic HER2+ biliary tract cancer (BTC) following the CHMP’s positive opinion in Apr 2025Approval was based on P-IIb (HERIZON-BTC-01) trial, which assessed anti-tumor activity of zanidatamab monotx. in HER2+ inoperable & advanced or metastatic BTCApproval…

ByRidhi Rastogi2 days ago

TOP 20

Top 20 Life Sciences Deals of 2022 by Total Deal Value

Shots:The technological advancement, shared cost, and the pursuit of combined extensive research are amongst the few pragmatic and mutual benefits that come with collaborations. Moreover, the risks involved in drug development plans get minimalized by opening the doors to new opportunities and commercializationWhen it comes to life science collaborations, companies seek beyond the…

ByPrince GiriFebruary 8, 2023

Zymeworks’ Zanidatamab Receives the NMPA’s Conditional Approval for the Treatment of Biliary Tract Cancer

Top 20 Life Sciences Deals of 2022 by Total Deal Value

Contact US

OUR INFORMATION

FOLLW US

Zymeworks’ Zanidatamab Receives the NMPA’s Conditional Approval for the Treatment of Biliary Tract Cancer

Top 20 Life Sciences Deals of 2022 by Total Deal Value

FOLLW US

Sign Up to Our Newsletter